Standard topical moxifloxacin therapy alone

PreclinicalSmall molecule

Standard topical moxifloxacin therapy alone is one of 24 small molecule programs targeting Keratitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

KeratitisActive, not recruiting

KeratitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

55 competitors in Keratitis

#DrugCompanyPhaseTrials

Avelox

Neoral

Levaquin

Rayos

Decadron

AAspen Global Incorporated

Approved

—6

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Acthar

1 8

OXERVATE

DDompé Farmaceutici S.p.A

Approved

1 9

Cenegermin

DDompé Farmaceutici S.p.A

Approved

1 10

Oxervate

DDompé Farmaceutici S.p.A

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Keratitis1 trial

Intrastromal Moxifloxacin as an Adjunctive Therapy in Recalcitrant Bacterial Keratitis

Recruiting·MMinia University·N/A·NCT07394257·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Standard topical moxifloxacin therapy alone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Standard topical moxifloxacin therapy alone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Standard topical moxifloxacin therapy alone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Minia University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMinia University

Standard topical moxifloxacin therapy alone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Keratitis1 trial

References

Drug Info

Quick Facts

Related News